# US Biopreservation Market > US Biopreservation Market Research Report: Size, Share, Trend Analysis By Applications (Cell and Tissue Culture, Gene and Drug Therapy, Clinical Applications, Regenerative Medicine), By Product Type (Biopreservation Media, Freezers, Cryogenic Storage Systems, Accessories), By End Users (Biotechnology Companies, Pharmaceutical Companies, Research Institutions, Hospitals, Clinics) and By Storage Type (Cryopreservation, Controlled Rate Freezing, Ultra-Low Temperature Storage) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.75% - **2024:** $ 1,200 Million - **2025:** $ 1,257 Million - **2035:** $ 2,000 Million - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Sartorius AG (DE), Lonza Group AG (CH), BioLife Solutions (US), Fresenius Kabi AG (DE), Cytiva (US), NantKwest (US), Cryoport Inc. (US) **Report ID:** MRFR/MED/13963-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-biopreservation-market-15490 --- ## Market Summary ## **US Biopreservation Market Overview** As per MRFR analysis, the US Biopreservation Market Size was estimated at 1.99 (USD Billion) in 2023. The US Biopreservation Market Industry is expected to grow from 2.08(USD Billion) in 2024 to 3.47 (USD Billion) by 2035. The US Biopreservation Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035). ### **Key US Biopreservation Market Trends Highlighted** The US Biopreservation Market is experiencing significant trends driven by a combination of technological advancements and increasing demand for biologics. The rise in biotechnology and life sciences, particularly in cell and gene therapies, is a key market driver, as these therapies require effective biopreservation methods to maintain the viability of cells and tissues. Additionally, the growing focus on personalized medicine is encouraging the development of tailored biological products, thereby increasing the need for efficient biopreservation solutions. Opportunities to be explored include the expansion of biobanks and the increased emphasis on regenerative medicine. Biobanks play a vital role in research by storing biological samples that require precise preservation to ensure their longevity and effectiveness in studies. Furthermore, as the US healthcare system shifts towards value-based care, there is a greater emphasis on the conservation of therapeutic products, allowing biopreservation techniques to gain traction. Recent trends indicate a heightened interest in advanced biopreservation techniques, such as cryopreservation and lyophilization. These methods not only enhance the stability of biological samples but also align with the need for improved storage solutions in the face of logistical challenges. Regulatory support from agencies like the FDA also plays an important role in paving the way for innovations in biopreservation methods, assuring end-users regarding the safety and efficacy of preserved product Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Biopreservation Market Drivers** ### **Increasing Demand for Biopreservation in Clinical Trials** The US Biopreservation Market Industry is experiencing significant growth due to the increasing number of clinical trials, particularly in the fields of oncology and precision medicine. According to the National Institutes of Health (NIH), the number of clinical trials in the United States has grown substantially, with over 300,000 active trials registered in 2023. This surge is driven by the need for innovative therapies and the focus on personalized medicine, which require the storage of biological samples under optimal conditions to maintain their integrity. Companies like Thermo Fisher Scientific and Sartorius provide biopreservation solutions that facilitate the storage and transport of these biological materials, enabling researchers to conduct their work more efficiently. The expansion of clinical trials not only creates a demand for advanced biopreservation technologies but also increases collaboration between research institutions and biobanks, further propelling the market forward. ### **Advancements in Biopreservation Technologies** Technological advancements in biopreservation methods such as cryopreservation and lyophilization have greatly influenced the US Biopreservation Market Industry. For instance, the introduction of automated cryopreservation systems has improved reproducibility and efficiency in sample storage, making it easier for laboratories to manage large biobanks. The Federal Drug Administration (FDA) regulations encourage the adoption of these technologies, thereby enhancing safety and performance. Furthermore, organizations like the American Association of Blood Banks promote the use of innovative preservation techniques, which are critical in ensuring the viability of stem cells and various biomaterials. As a result, these advancements not only support ongoing research but also lead to increased market growth. ### **Rising Prevalence of Chronic Diseases** The US Biopreservation Market Industry benefits from the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders. According to the Centers for Disease Control and Prevention (CDC), nearly 60% of adults in the United States live with a chronic illness. This alarming trend has driven healthcare providers to explore innovative treatments, thus increasing the need for biobanking and biopreservation to store biological samples and tissues. Organizations such as the American Cancer Society play a pivotal role in funding and promoting research on cancer, further necessitating effective biopreservation methods to ensure sample integrity. As chronic diseases become a larger health concern, the demand for biopreservation solutions aimed at aiding research and therapy development continues to grow. ### **Support from Government Initiatives and Funding** Government initiatives and funding are substantial drivers for the growth of the US Biopreservation Market Industry. Various government agencies, including the NIH and the FDA, are actively supporting research and development in the field of biopreservation through grants and funding programs. For instance, the NIH invests billions of dollars annually in various research activities, which often involve biobanking and the use of preserved biological samples. Additionally, recent policy changes aimed at advancing biomedical research, such as the US government's commitment to enhance data preservation in research settings, have driven investment into biopreservation technologies. This government backing not only facilitates innovation but also encourages the participation of private sector companies to develop and improve biopreservation methods, further boosting the market. ## **US Biopreservation Market Segment Insights** ### **Biopreservation Market Application Insights** The Application segment of the US Biopreservation Market plays a crucial role in the overall landscape, enabling advancements across various healthcare domains. The increasing focus on cell and tissue culture has propelled its importance, driven by rising demand for effective treatment solutions in regenerative medicine. As this field grows, the need for reliable biopreservation techniques to maintain cellular viability becomes more evident, leading to improved patient outcomes. Similarly, gene and drug therapy applications are gaining momentum due to their potential to target genetic disorders, which consequently underlines the significance of robust preservation protocols to ensure the efficacy of therapeutic products. The regulatory landscape in the United States further enhances the necessity for stringent biopreservation methods in clinical applications, where maintaining the integrity of biological materials is paramount. Moreover, the growing emphasis on research and development (R&D) within regenerative medicine is expected to boost the associated biopreservation needs, making it a dynamic area of investment. The US has observed a surge in initiatives aimed at exploring novel biopreservation techniques, accentuated by collaboration between academic institutions and industry leaders. This convergence leads to innovative solutions tailored to specific applications, thus showcasing the importance of the Application segment in driving the future trajectory of the US Biopreservation Market. With a diverse range of applications, the market is well-positioned to respond to the evolving demands of healthcare and biotechnological advancements. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Biopreservation Market Product Type Insights** The US Biopreservation Market showcases a diverse array of product types essential for maintaining biological samples. Among these, Biopreservation Media plays a crucial role by providing the necessary environment for cell cultures, tissues, and organs, enabling researchers to ensure the viability and functionality of biological materials. Freezers are equally significant, designed to preserve samples at ultra-low temperatures, thus preventing cellular degradation. Cryogenic Storage Systems further enhance preservation efforts, offering long-term storage solutions that maintain the integrity of valuable biological materials, critical for Research and Development initiatives. Accessories such as vials, pipettes, and storage containers are equally indispensable, supporting the efficient handling and tracking of samples. As the US Biopreservation Market grows, driven by advancements in biotechnology and increasing demand for regenerative medicine, each product type will continue to play a vital role in enhancing the overall effectiveness and reliability of biopreservation practices. The market data indicates an ongoing trend toward innovation, which will further propel the segmentation within this industry. ### **Biopreservation Market End User Insights** The End User segment of the US Biopreservation Market encompasses various critical entities that greatly contribute to the advancement of the industry. Biotechnology companies play a pivotal role by utilizing biopreservation methods to maintain the viability of biological materials for research and product development. Pharmaceutical companies increasingly rely on biopreservation techniques to ensure the integrity of their drugs, particularly in the context of personalized medicine and complex biologics. Research institutions leverage these methods to preserve biological samples for ongoing research, which contributes significantly to scientific innovations. Moreover, hospitals and clinics are key players, as they utilize biopreservation for the storage of blood, tissues, and organs, which enhances patient care and treatment outcomes. The rising focus on regenerative medicine and cellular therapies strengthens the demand within these sectors, particularly for safe and effective storage solutions. With the growth of these end-users, the US Biopreservation Market is poised for considerable developments, aligning with increasing research activities and advancements in healthcare technologies. The segment demonstrates robust growth potential as it adapts to the evolving needs of various industries. ### **Biopreservation Market Storage Type Insights** The Storage Type segment of the US Biopreservation Market encompasses various methods crucial for preserving biological materials, each playing a significant role in the healthcare and research fields. Cryopreservation is a dominant technique that allows for the long-term storage of cells, tissues, and organs by freezing them at very low temperatures, thereby maintaining their viability for future use. This method is essential for ensuring the availability of stem cells and reproductive cells for fertility treatments and transplants. Controlled Rate Freezing allows for precise temperature management during the freezing process, reducing the formation of ice crystals that can damage biological samples, which is particularly crucial in the preservation of sensitive tissues and organs. Ultra-Low Temperature Storage operates at extreme sub-zero conditions, providing a stable environment for the preservation of a wide array of biomaterials. The increasing demand for these storage solutions is driven by advancements in Research and Development, expanding biobanks, and the growing field of regenerative medicine. Each method not only supports diverse applications in clinical settings but also enhances Research and Development opportunities, aligning with the broader US Biopreservation Market growth trends. Ensuring the integrity and viability of stored biological materials remains paramount as the industry continues to evolve. ## **US Biopreservation Market Key Players and Competitive Insights** The US Biopreservation Market is characterized by a rapidly evolving landscape that is shaped by advancements in technology, increasing demand for biopreserved products, and a rising awareness of the importance of cell and tissue preservation. Key participants in this market include biopharmaceutical companies, research institutions, and clinical laboratories, which rely on biopreservation solutions to extend the shelf life and maintain the integrity of biological samples. As the demand for personalized medicine and regenerative therapies continues to grow, the competitive insights reveal a market where innovation, strategic partnerships, and mergers and acquisitions play crucial roles in ensuring companies can adapt to the changing environment and meet regulatory challenges. The focus lies on developing and improving biopreservation materials, methodologies, and storage techniques that cater to the unique needs of various sectors within the life sciences, leading to a competitive edge for players who can successfully harness these advancements. Lonza has established a strong foothold in the US Biopreservation Market, with notable strengths in its extensive portfolio of biopreservation products and services. The company leverages its deep expertise in cell and gene therapy, offering solutions that cater to the unique needs of researchers and biopharmaceutical manufacturers. Lonza's robust infrastructure allows for efficient scaling of biopreservation solutions, positioning it advantageously against competitors. Their commitment to innovation is evident through ongoing research and development initiatives aimed at creating next-generation preservation techniques that enhance sample viability and functionality. Furthermore, Lonza's established relationships with leading biotech firms and research institutions facilitate collaboration and knowledge exchange, bolstering its visibility and influence in the US market. ReproCELL has also made significant inroads into the US Biopreservation Market, primarily focusing on cell-based assays and stem cell technologies. Known for its specialized services, the company offers a comprehensive range of biopreservation solutions tailored for cell lines, tissues, and organs. This enables them to address the specific needs of customers in regenerative medicine and drug discovery sectors. ReproCELL has acquired other companies in recent years to bolster its service offerings, enhancing its position in the market and expanding its technological capabilities. These strategic mergers and acquisitions have allowed ReproCELL to combine expertise and resources, enabling it to better serve the US market. With a focus on innovation, the company is committed to providing advanced biopreservation solutions that ensure the quality and longevity of biological samples, thus solidifying its competitive advantage in this burgeoning sector. ### **Key Companies in the US Biopreservation Market Include** ## **US Biopreservation Market Industry Developments** Recent developments in the US Biopreservation Market highlight significant growth potential and activity among key players such as Lonza, ReproCELL, Tecan, Bluebird Bio, Thermo Fisher Scientific, Fresenius Kabi, Corning, Vitae Health, Cytiva, Pall Corporation, Biolife Solutions, Asymptote, Sartorius, Merck KGaA, and SigmaAldrich. In February 2023, Thermo Fisher Scientific acquired PPD, enhancing its capabilities in biopreservation and increasing service offerings. Additionally, in April 2023, Pall Corporation announced a partnership with Cytiva to improve biopharmaceutical workflows, showcasing collaborative advancements in the sector. The market has seen a valuation increase of over 10% in just the past year, partly driven by rising demand for biopreservation solutions in biobanks and research institutions. Regulatory support from the U.S. Food and Drug Administration has also streamlined processes for biopreservation technologies, aiding market growth. In the last 2-3 years, significant investments in Research and Development have been noted in organizations such as Merck KGaA and Fresenius Kabi, further driving innovation and improving biopreservation methodologies. Overall, the US Biopreservation Market remains dynamic, with numerous collaborations and acquisitions shaping its future trajectory. ## **US Biopreservation Market Segmentation Insights** ### **Biopreservation Market Application Outlook** ### **Biopreservation Market Product Type Outlook** ### **Biopreservation Market End User Outlook** ### **Biopreservation Market Storage Type Outlook** ## Market Drivers ### Expansion of Biobanking Initiatives The expansion of biobanking initiatives is a critical driver for the biopreservation market. Biobanks play a vital role in collecting, storing, and managing biological samples for research and clinical purposes. With the number of biobanks in the US increasing significantly, the demand for effective biopreservation solutions is expected to rise correspondingly. It is estimated that the biobanking sector will require an investment of over $500 million in biopreservation technologies by 2027. This growth is fueled by the need for high-quality samples in various research fields, including genomics, oncology, and infectious diseases. As biobanks continue to proliferate, the biopreservation market is likely to experience substantial growth. ### Growing Focus on Personalized Medicine The biopreservation market is poised for growth due to the increasing focus on [personalized medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925). As healthcare shifts towards tailored treatment approaches, the demand for biopreservation solutions that can effectively store and manage biological samples is on the rise. The market for personalized medicine is projected to reach $2 trillion by 2030, indicating a substantial opportunity for biopreservation technologies. This trend is driven by advancements in genomics and proteomics, which require precise preservation methods to maintain sample quality. Consequently, the biopreservation market is likely to see heightened investment and innovation as stakeholders seek to support the evolving landscape of personalized healthcare. ### Increased Awareness of Food Safety Standards The biopreservation market is also being driven by increased awareness of food safety standards among consumers and regulatory bodies. As foodborne illnesses remain a significant public health concern, there is a growing emphasis on implementing effective preservation methods to ensure food safety. The food industry is projected to invest approximately $1 billion in biopreservation technologies by 2025, reflecting a commitment to enhancing food quality and safety. This trend is likely to lead to the adoption of biopreservation techniques that utilize natural preservatives and microbial agents, thereby promoting the growth of the biopreservation market. As consumers demand safer food products, the market is expected to respond with innovative preservation solutions. ### Surge in Research and Development Activities The biopreservation market is significantly influenced by the surge in research and development (R&D) activities across various sectors, particularly in biotechnology and pharmaceuticals. With R&D expenditures in the US reaching approximately $200 billion annually, there is a growing emphasis on developing advanced preservation methods for biological samples. This trend is expected to drive the demand for biopreservation solutions, as researchers require reliable methods to maintain the integrity of samples over extended periods. Furthermore, the increasing number of clinical trials and biobanking initiatives is likely to further propel the biopreservation market, as these activities necessitate stringent preservation protocols to ensure sample viability. ### Rising Adoption of Biopreservation in Healthcare The biopreservation market is experiencing a notable increase in adoption within the healthcare sector. This trend is driven by the growing need for effective preservation methods for biological materials, such as tissues and organs. The healthcare industry is projected to invest approximately $1.5 billion in biopreservation technologies by 2026, reflecting a compound annual growth rate (CAGR) of around 10%. This investment is largely influenced by the rising prevalence of chronic diseases and the need for organ transplants, which necessitate reliable preservation techniques. As healthcare providers seek to enhance patient outcomes, the biopreservation market is likely to benefit from this heightened focus on innovative preservation solutions. ## Future Outlook The [Biopreservation Market](https://www.marketresearchfuture.com/reports/biopreservation-market-6407) is projected to grow at a 4.75% CAGR from 2025 to 2035, driven by advancements in storage technologies and increasing demand for biopharmaceuticals. **New opportunities:** - Development of advanced cryopreservation solutions for cell therapies. Integration of IoT in biopreservation monitoring systems. Expansion of biopreservation services for personalized medicine applications. By 2035, the biopreservation market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Cell and Tissue Culture (Largest) vs. Gene and Drug Therapy (Fastest-Growing) The US biopreservation market is characterized by distinct application segments, with Cell and Tissue Culture leading the charge due to its widespread use in research and clinical settings. This segment holds the largest market share as it serves as an essential component in various biopharmaceutical and therapeutic development processes. Meanwhile, Gene and Drug Therapy is becoming increasingly important as advancements in personalized medicine drive its adoption, marking it as the fastest-growing segment in the market. Growth trends indicate a robust dynamic within these application segments, fueled by significant investments in biotechnology and increasing demand for innovative therapies. The rise of regenerative medicine and the focus on enhancing clinical applications further augment the market's expansion. Additionally, supportive government policies and funding initiatives are propelling research in these areas, thus shaping their growth trajectories significantly. Cell and Tissue Culture (Dominant) vs. Gene and Drug Therapy (Emerging) Cell and Tissue Culture represents the dominant application in the market, primarily due to its critical role in supporting drug discovery and development processes across biopharmaceuticals. It benefits from a well-established infrastructure and a strong base of scientific research and clinical usage. In contrast, Gene and Drug Therapy is an emerging segment that showcases rapid innovation with the promise of tailored treatments for various diseases. As research progresses, this segment anticipates increased commercialization of advanced therapies, necessitating sophisticated biopreservation methodologies. The divergence in their market positions highlights the stabilization of established practices versus the dynamic nature of emerging technologies seeking to redefine therapeutic options. ### By Product Type: Freezers (Largest) vs. Biopreservation Media (Fastest-Growing) The US biopreservation market is experiencing a diverse distribution of market share among its product types. Freezers hold the largest share, primarily due to their essential role in maintaining the integrity of biological samples. Biopreservation media, while currently smaller in market size, is rapidly gaining traction as advanced formulations are developed, tailored for specific applications, and optimized for performance. The growth trends within this segment are largely driven by the increasing demand for biobanking and regenerative medicine. Innovations in cryogenic storage and enhancements in biopreservation media formulations are propelling this segment forward. Rising investments in research and development across biotechnology firms are also contributing significantly, fostering a landscape ripe for both established and emerging product categories. Freezers (Dominant) vs. Biopreservation Media (Emerging) Freezers, as the dominant segment, are crucial for preserving cellular materials and biological samples, ensuring long-term viability and reducing degradation risks. Their robustness and reliability make them a staple in laboratories and biobanks across various sectors. In contrast, biopreservation media represents an emerging value that is gaining ground. This segment includes various formulation types designed to enhance the survival of cells during the preservation process. As biopreservation media continues to evolve with scientific advancements, it is becoming indispensable in applications like tissue engineering and stem cell research, positioning itself as a vital component of the biopreservation ecosystem. ### By End User: Biotechnology Companies (Largest) vs. Pharmaceutical Companies (Fastest-Growing) In the US biopreservation market, the distribution of market share among end users reveals that biotechnology companies hold the largest share, driven by their extensive research and development activities. This segment capitalizes on advancements in cellular therapies and regenerative medicine, thus dominating the biopreservation landscape. In contrast, pharmaceutical companies, while currently smaller in overall share, are rapidly gaining ground, attributable to increasing investments in biologics and personalized medicine. The growth trend among these segments is significantly influenced by innovation in biopreservation technologies and the rising demand for the storage of biological samples. The expansion of research institutions and hospitals also plays a crucial role, as they require effective preservation solutions for clinical trials and patient samples. Additionally, the growing emphasis on regenerative medicine and the need for safe storage of sensitive biological materials are propelling the growth of both biotechnology and pharmaceutical companies in this market. Biotechnology Companies (Dominant) vs. Pharmaceutical Companies (Emerging) Biotechnology companies are recognized as the dominant players in the US biopreservation market, leveraging cutting-edge technologies and extensive R&D to meet the demands of various applications, such as cellular and gene therapies. Their capacity for innovation ensures a steady flow of advanced biopreservation solutions, which are vital for maintaining the viability of biological materials. On the other hand, pharmaceutical companies are emerging as significant contributors, as they adapt to market needs by investing in biopreservation technologies to ensure the stability of biologics and vaccines. This evolving landscape fosters collaboration between these segments, driving advancements and enhancing the overall efficacy of biopreservation methods. ### By Storage Type: Cryopreservation (Largest) vs. Ultra-Low Temperature Storage (Fastest-Growing) The US biopreservation market showcases a diverse range of storage types crucial for maintaining biological materials. Cryopreservation leads the segment, holding a significant market share due to its established application in preserving cells, tissues, and organs. In contrast, Ultra-Low Temperature Storage, although smaller in share, is rapidly gaining traction among biopharmaceutical companies because of its ability to maintain sample integrity over extended periods without degradation. Growth trends in the US biopreservation market are being driven by advancements in cryopreservation techniques and the increasing demand for biobanking and regenerative medicine. The rapid expansion of the clinical research sector and the need for efficient long-term storage solutions are propelling Ultra-Low Temperature Storage forward. As regulatory frameworks evolve and innovative technologies emerge, both Cryopreservation and Ultra-Low Temperature Storage are set to play pivotal roles in the market's future developments. Cryopreservation (Dominant) vs. Controlled Rate Freezing (Emerging) Cryopreservation is currently the dominant storage method in the US biopreservation market, celebrated for its ability to preserve cellular structures and maintain viability. This technique ensures that biological materials are kept at optimal temperatures, minimizing ice crystal formation. On the other hand, Controlled Rate Freezing is gaining popularity as an emerging technique due to its precise temperature management, which significantly enhances the recovery rates of cells post-thawing. While Cryopreservation remains essential for a variety of applications, Controlled Rate Freezing's ability to improve outcomes in stem cell therapy and tissue engineering is driving its growth. Both methods are imperative for advancements in healthcare and research, securing their positions in an increasingly competitive market. ## Competitive Benchmarking The biopreservation market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations. Key growth drivers include the increasing demand for biopharmaceuticals, advancements in preservation technologies, and a heightened focus on regulatory compliance. Major players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and BioLife Solutions (US) are strategically positioned to leverage these trends. Thermo Fisher Scientific (US) emphasizes innovation through its extensive portfolio of biopreservation products, while Merck KGaA (DE) focuses on expanding its global footprint through strategic partnerships. BioLife Solutions (US) is dedicated to enhancing its product offerings, particularly in cell and gene therapy, thereby shaping a competitive environment that prioritizes technological advancement and market responsiveness. Key business tactics within the biopreservation market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their market positions through strategic acquisitions and partnerships, thereby enhancing their competitive edge. In October 2025, Thermo Fisher Scientific (US) announced the launch of a new line of biopreservation media designed specifically for cell therapy applications. This strategic move is likely to bolster its market share by addressing the growing demand for advanced preservation solutions in the biopharmaceutical sector. The introduction of this product line not only reinforces Thermo Fisher's commitment to innovation but also positions the company as a leader in the rapidly evolving cell therapy market. In September 2025, Merck KGaA (DE) expanded its collaboration with a leading biotechnology firm to enhance its biopreservation solutions. This partnership aims to develop next-generation preservation technologies that could significantly improve the stability and viability of biological samples. Such strategic alliances are indicative of Merck's focus on innovation and its intent to remain competitive in a market that increasingly values cutting-edge technology. In August 2025, BioLife Solutions (US) acquired a smaller biopreservation company to enhance its product portfolio and expand its market reach. This acquisition is strategically important as it allows BioLife to integrate new technologies and expertise, thereby strengthening its position in the cell and gene therapy markets. The move reflects a broader trend of consolidation within the industry, as companies seek to enhance their capabilities and offerings through strategic acquisitions. As of November 2025, current competitive trends in the biopreservation market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into preservation processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological innovation, supply chain reliability, and sustainable practices. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the biopreservation market. ## Recent News & Developments Recent developments in the US Biopreservation Market highlight significant growth potential and activity among key players such as Lonza, ReproCELL, Tecan, Bluebird Bio, Thermo Fisher Scientific, Fresenius Kabi, Corning, Vitae Health, Cytiva, Pall Corporation, Biolife Solutions, Asymptote, Sartorius, Merck KGaA, and SigmaAldrich. In February 2023, Thermo Fisher Scientific acquired PPD, enhancing its capabilities in biopreservation and increasing service offerings. Additionally, in April 2023, Pall Corporation announced a partnership with Cytiva to improve biopharmaceutical workflows, showcasing collaborative advancements in the sector. The market has seen a valuation increase of over 10% in just the past year, partly driven by rising demand for biopreservation solutions in biobanks and research institutions. Regulatory support from the U.S. Food and Drug Administration has also streamlined processes for biopreservation technologies, aiding market growth. In the last 2-3 years, significant investments in Research and Development have been noted in organizations such as Merck KGaA and Fresenius Kabi, further driving innovation and improving biopreservation methodologies. Overall, the US Biopreservation Market remains dynamic, with numerous collaborations and acquisitions shaping its future trajectory. ## Report Scope | MARKET SIZE 2024 | 1200.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1257.0(USD Million) | | MARKET SIZE 2035 | 2000.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.75% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Sartorius AG (DE), Lonza Group AG (CH), BioLife Solutions (US), Fresenius Kabi AG (DE), Cytiva (US), NantKwest (US), Cryoport Inc. (US) | | Segments Covered | Application, Product Type, End User, Storage Type | | Key Market Opportunities | Advancements in biopreservation technologies enhance product shelf life and safety in food and pharmaceuticals. | | Key Market Dynamics | Rising demand for biopreservation solutions driven by regulatory changes and technological advancements in the US. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US biopreservation market in 2024?** A: The overall market valuation was $1200.0 Million in 2024. **Q: What is the projected market valuation for the US biopreservation market by 2035?** A: The projected valuation for 2035 is $2000.0 Million. **Q: What is the expected CAGR for the US biopreservation market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 4.75%. **Q: Which application segment had the highest valuation in 2024?** A: In 2024, the Gene and Drug Therapy application segment had a valuation of $400.0 Million to $700.0 Million. **Q: What are the key product types in the US biopreservation market?** A: Key product types include Biopreservation Media, Freezers, Cryogenic Storage Systems, and Accessories. **Q: Which end user segment is projected to grow significantly in the US biopreservation market?** A: Pharmaceutical Companies, with a valuation range of $360.0 Million to $600.0 Million, are projected to grow significantly. **Q: What is the valuation range for Cryogenic Storage Systems in 2024?** A: The valuation range for Cryogenic Storage Systems in 2024 was $350.0 Million to $600.0 Million. **Q: Who are the leading players in the US biopreservation market?** A: Key players include Thermo Fisher Scientific, Merck KGaA, Sartorius AG, and BioLife Solutions. **Q: What storage type is expected to dominate the US biopreservation market?** A: Ultra-Low Temperature Storage, with a projected valuation of $500.0 Million to $800.0 Million, is expected to dominate. **Q: How does the market performance of biotechnology companies compare to hospitals in 2024?** A: In 2024, biotechnology companies had a valuation range of $240.0 Million to $400.0 Million, similar to hospitals. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biopreservation-market-15490*